Markéta Palácová

2.8k total citations
28 papers, 254 citations indexed

About

Markéta Palácová is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Markéta Palácová has authored 28 papers receiving a total of 254 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 10 papers in Genetics. Recurrent topics in Markéta Palácová's work include Advanced Breast Cancer Therapies (11 papers), BRCA gene mutations in cancer (10 papers) and Breast Cancer Treatment Studies (8 papers). Markéta Palácová is often cited by papers focused on Advanced Breast Cancer Therapies (11 papers), BRCA gene mutations in cancer (10 papers) and Breast Cancer Treatment Studies (8 papers). Markéta Palácová collaborates with scholars based in Czechia, France and Spain. Markéta Palácová's co-authors include Marek Svoboda, Rostislav Vyzula, Pavel Fabián, Katarína Petráková, Jiří Šáňa, Ondřej Slabý, Martina Rédová, Jiří Navrátil, Johanna Mattson and Maureen Trudeau and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Breast Cancer Research and Treatment.

In The Last Decade

Markéta Palácová

26 papers receiving 235 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Markéta Palácová Czechia 8 135 104 92 62 56 28 254
Etienne Müller France 7 82 0.6× 117 1.1× 59 0.6× 44 0.7× 63 1.1× 9 215
Marie‐Emmanuelle Legrier France 6 90 0.7× 95 0.9× 59 0.6× 76 1.2× 18 0.3× 9 220
Lingzhu Wen China 10 181 1.3× 153 1.5× 165 1.8× 96 1.5× 49 0.9× 24 341
Joshua C. Farris United States 7 141 1.0× 210 2.0× 94 1.0× 40 0.6× 27 0.5× 21 325
Rachel Marty United States 4 164 1.2× 157 1.5× 105 1.1× 37 0.6× 43 0.8× 4 340
SJ Isakoff United States 8 300 2.2× 110 1.1× 159 1.7× 107 1.7× 55 1.0× 29 347
Anita Trapman-Jansen Netherlands 8 154 1.1× 128 1.2× 83 0.9× 51 0.8× 50 0.9× 13 304
Michael Peoples United States 9 105 0.8× 181 1.7× 59 0.6× 36 0.6× 29 0.5× 16 267
Ina Menzl United States 5 162 1.2× 190 1.8× 56 0.6× 65 1.0× 96 1.7× 8 349
R. Dent Canada 5 254 1.9× 88 0.8× 154 1.7× 70 1.1× 92 1.6× 12 337

Countries citing papers authored by Markéta Palácová

Since Specialization
Citations

This map shows the geographic impact of Markéta Palácová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markéta Palácová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markéta Palácová more than expected).

Fields of papers citing papers by Markéta Palácová

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markéta Palácová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markéta Palácová. The network helps show where Markéta Palácová may publish in the future.

Co-authorship network of co-authors of Markéta Palácová

This figure shows the co-authorship network connecting the top 25 collaborators of Markéta Palácová. A scholar is included among the top collaborators of Markéta Palácová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markéta Palácová. Markéta Palácová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Obermannová, Radka, Iveta Selingerová, Regina Demlová, et al.. (2025). Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients with solid cancer following prime BNT162b2 COVID-19 vaccination: results from phase IV CoVigi trial. Therapeutic Advances in Medical Oncology. 17. 22760960–22760960.
2.
Freyer, Gilles, Noelia Martínez-Jáñez, Bożena Kukiełka-Budny, et al.. (2024). Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study. The Breast. 74. 103681–103681. 1 indexed citations
3.
Borštnar, Simona, Markéta Palácová, Aleksandra Łacko, et al.. (2022). Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial. Radiology and Oncology. 56(2). 238–247. 2 indexed citations
4.
Campone, Mario, Michelino De Laurentiis, Claudio Zamagni, et al.. (2022). Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial. Breast Cancer Research and Treatment. 193(1). 95–103. 9 indexed citations
5.
Palácová, Markéta. (2019). Hormonal therapy in premenopausal patients with SR-positive, HER2-negative breast cancer. 13(1). 24–28. 1 indexed citations
6.
Foretová, Lenka, Marie Navrátilová, Marek Svoboda, et al.. (2019). Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer. Klinicka onkologie. 32(Suppl 2). 1 indexed citations
7.
8.
9.
Foretová, Lenka, Eva Macháčková, Markéta Palácová, et al.. (2016). Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome. Klinicka onkologie. 29(Suppl 1). S9–S13. 7 indexed citations
10.
Navrátil, Jiří, Pavel Fabián, Markéta Palácová, et al.. (2015). Triple Negative Breast Cancer. Klinicka onkologie. 28(6). 406–415. 25 indexed citations
11.
Svoboda, Marek, Jiří Šáňa, Martina Rédová, et al.. (2012). MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagnostic Pathology. 7(1). 31–31. 52 indexed citations
12.
Foretová, Lenka, Jaroslav Štěrba, Jiří Lisý, et al.. (2012). [Li-Fraumeni syndrome - a proposal of complex prevention care for carriers of TP53 mutation with total-body MRI].. PubMed. 25 Suppl. S49–54. 1 indexed citations
13.
Svoboda, M., Jiří Navrátil, Markéta Palácová, et al.. (2012). [Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].. PubMed. 25(3). 188–98. 3 indexed citations
14.
Coufal, Oldřich, Vuk Fait, Lenka Foretová, et al.. (2011). Chirurgická léčba karcinomu prsu.
15.
Foretová, Lenka, Katarína Petráková, Markéta Palácová, et al.. (2010). Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience.. PubMed. 23(6). 388–400. 6 indexed citations
16.
Petráková, Katarína, Rudolf Nenutil, Pavel Fabián, et al.. (2008). [Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients].. PubMed. 21(5). 303–8. 1 indexed citations
17.
Svoboda, Marek, Pavel Fabián, Lenka Radová, et al.. (2008). The impact of signaling pathways stimulated by HER2 receptor on prediction of clinical outcome in metastatic breast cancer patients treated with trastuzumab. Journal of Clinical Oncology. 26(15_suppl). 1048–1048. 1 indexed citations
18.
Svoboda, Marek, Pavel Fabián, Markéta Palácová, et al.. (2007). Brain metastases in breast cancer: a retrospective cohort studyof 187 patients and prognostic markers determination.. Breast Cancer Research and Treatment. 106. 1 indexed citations
19.
Foretová, Lenka, Katarína Petráková, Markéta Palácová, et al.. (2006). Genetic and Preventive Services for Hereditary Breast and Ovarian Cancer in the Czech Republic. Hereditary Cancer in Clinical Practice. 4(1). 3–6. 4 indexed citations
20.
Bednařík, Otakar, et al.. (2002). [Primary prevention of malignant tumors].. PubMed. 141(22). 691–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Etienne Müller Breakdown of academic impact, for papers by Marie‐Emmanuelle Legrier Breakdown of academic impact, for papers by Lingzhu Wen Breakdown of academic impact, for papers by Joshua C. Farris Breakdown of academic impact, for papers by Rachel Marty Breakdown of academic impact, for papers by SJ Isakoff Breakdown of academic impact, for papers by Anita Trapman-Jansen Breakdown of academic impact, for papers by Michael Peoples Breakdown of academic impact, for papers by Ina Menzl Breakdown of academic impact, for papers by R. Dent
Rankless by CCL
2026